| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.14 | 0.01 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | -0.22 | 0.01 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.1 | 0.01 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | -0.084 | 0.01 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | -0.099 | 0.01 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | -0.088 | 0.01 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | -0.09 | 0.01 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | -0.24 | 0.01 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.095 | 0.01 |